new glp-1 agonist receptor agonists show promise in treating substance use disorders GLP-1 Agonists in Cardiovascular Diseases:
Description
Thats why theres a lot of excitement around a new pill form of the drug
From weight loss breakthroughsto type 2 diabetes management, and even anti-aging medicine, these treatments offer extraordinary promise.But with innovation comes risk
Leah Joseph at Josephcarerx Clarifies the Key Differences Between GLP-1 and Ozempic to Help You Make Informed Health Decisions.
Ph 2 datathat showed weight loss of between 9.4% and 14.7% after 36 weeks on the drug compared to 2.3% for the placebo group and is currently in Ph 3
Ozempic can be difficult to get and isn't appropriate for everyone
It starts in the desert
